Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide

被引：30

作者：

Giagounidis, A. A. N. ^{[1
]}

Kulasekararaj, A. ^{[2
]}

Germing, U. ^{[3
]}

Radkowski, R. ^{[1
]}

Haase, S. ^{[1
]}

Petersen, P. ^{[1
]}

Goehring, G. ^{[4
]}

Buesche, G. ^{[4
]}

Aul, C. ^{[1
]}

Mufti, G. J. ^{[2
]}

Platzbecker, U. ^{[5
]}

机构：

[1] St Johannes Hosp, Katholisches Klinikum Duisburg, Duisburg, Germany

[2] Kings Coll Hosp London, London, England

[3] Univ Dusseldorf, D-40225 Dusseldorf, Germany

[4] Hannover Med Sch, D-30623 Hannover, Germany

[5] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, D-01062 Dresden, Germany

来源：

LEUKEMIA | 2012年 / 26卷 / 04期

关键词：

MYELODYSPLASTIC SYNDROME; RISK;

D O I：

10.1038/leu.2011.268

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：855 / 858

页数：5

共 11 条

[1] Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-α:: a phase II study [J].

Giagounidis, AAN ;

Haase, S ;

Germing, U ;

Schlegelberger, B ;

Wilkens, L ;

Büsche, G ;

Kreipe, HH ;

Wysk, J ;

Grips, KH ;

Grabenhorst, U ;

Rothmann, F ;

Lübbert, M ;

Ganser, A ;

Aivado, M ;

Heinsch, M ;

Aul, C .

ANNALS OF HEMATOLOGY, 2005, 84 (06) :389-394

[2] Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes [J].

Giagounidis, Aristoteles ;

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Muus, Petra ;

Platzbecker, Uwe ;

Sanz, Guillermo ;

Cripe, Larry ;

Von Lilienfeld-Toal, Marie ;

Wells, Richard A. .

ANNALS OF HEMATOLOGY, 2008, 87 (05) :345-352

[3] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression [J].

Goehring, Gudrun ;

Giagounidis, Aristoteles ;

Buesche, Guntram ;

Kreipe, Hans Heinrich ;

Zimmermann, Martin ;

Hellstroem-Lindberg, Eva ;

Aul, Carlo ;

Schlegelberger, Brigitte .

ANNALS OF HEMATOLOGY, 2010, 89 (04) :365-374

[4] Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q [J].

Gohring, Gudrun ;

Lange, Kathrin ;

Hofmann, Winfried ;

Nielsen, Kirsten Vang ;

Hellstrom-Lindberg, Eva ;

Roy, Lydia ;

Morgan, Michael ;

Kreipe, Hans ;

Buesche, Guntram ;

Giagounidis, Aristoteles ;

Schlegelberger, Brigitte .

BLOOD, 2010, 116 (21) :18-18

[5] Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression [J].

Jadersten, Martin ;

Saft, Leonie ;

Pellagatti, Andrea ;

Goehring, Gudrun ;

Wainscoat, James S. ;

Boultwood, Jacqueline ;

Porwit, Anna ;

Schlegelberger, Brigitte ;

Hellstrom-Lindberg, Eva .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12) :1762-1766

[6] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion [J].

List, Alan ;

Dewald, Gordon ;

Bennett, John ;

Giagounidis, Aristotle ;

Raza, Azra ;

Feldman, Eric ;

Powell, Bayard ;

Greenberg, Peter ;

Thomas, Deborah ;

Stone, Richard ;

Reeder, Craig ;

Wride, Kenton ;

Patin, John ;

Schmidt, Michele ;

Zeldis, Jerome ;

Knight, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1456-1465

[7] Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q [J].

Mallo, M. ;

Cervera, J. ;

Schanz, J. ;

Such, E. ;

Garcia-Manero, G. ;

Luno, E. ;

Steidl, C. ;

Espinet, B. ;

Vallespi, T. ;

Germing, U. ;

Blum, S. ;

Ohyashiki, K. ;

Grau, J. ;

Pfeilstoecker, M. ;

Hernandez, J. M. ;

Noesslinger, T. ;

Giagounidis, A. ;

Aul, C. ;

Calasanz, M. J. ;

Martin, M. L. ;

Valent, P. ;

Collado, R. ;

Haferlach, C. ;

Fonatsch, C. ;

Luebbert, M. ;

Stauder, R. ;

Hildebrandt, B. ;

Krieger, O. ;

Pedro, C. ;

Arenillas, L. ;

Sanz, M. A. ;

Valencia, A. ;

Florensa, L. ;

Sanz, G. F. ;

Haase, D. ;

Sole, F. .

LEUKEMIA, 2011, 25 (01) :110-120

[8] Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma [J].

Misgeld, E ;

Germing, U ;

Aul, C ;

Gattermann, N .

LEUKEMIA RESEARCH, 2001, 25 (01) :95-98

[9] The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells [J].

Mohr, Brigitte ;

Oelschlaegel, Uta ;

Thiede, Christian ;

Stewart, Michelle Meredyth ;

Ehninger, Gerhard ;

Platzbecker, Uwe .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (03) :430-431

[10] Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes [J].

Sekeres, Mikkael A. ;

Maciejewski, Jaroslaw P. ;

Giagounidis, Aristotle A. N. ;

Wride, Kenton ;

Knight, Robert ;

Raza, Azra ;

List, Alan F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5943-5949

← 1 2 →